ArticleAntimicrobial agents and chemotherapy2019
APX001 Pharmacokinetic/Pharmacodynamic Target Determination against
Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers.Antimicrobial agents and chemotherapy · 2023Trial
- Fosmanogepix: A comprehensive review of its origin, mechanism, antifungal efficacy, and resistance (Review).Biomedical reports · 2026Review
- New Perspectives on Antimicrobial Agents: Fosmanogepix.Antimicrobial agents and chemotherapy · 2026Review
- Manogepix demonstrates potentAntimicrobial agents and chemotherapy · 2026Article
- Evaluation of anAntimicrobial agents and chemotherapy · 2026Article
- The Four Critical Priority Fungi According to the World Health Organization and the Hope for New Therapies: A Focus on Cell Wall Antifungal Targets.Journal of fungi (Basel, Switzerland) · 2026Review
- Article
- Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease.Clinical microbiology reviews · 2024Review
- Antifungal Susceptibility ofPathogens (Basel, Switzerland) · 2024Article
- Article
- Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents.Journal of fungi (Basel, Switzerland) · 2022Review
- Therapeutic Approaches for CombatingCurrent drug targets · 2022Review
- The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin.Drugs · 2021Review
- Article
- Review
- Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.The Lancet. Infectious diseases · 2021Review
- Manogepix, the Active Moiety of the Investigational Agent Fosmanogepix, DemonstratesAntimicrobial agents and chemotherapy · 2021Article
- Model-Informed Drug Development for Anti-Infectives: State of the Art and Future.Clinical pharmacology and therapeutics · 2021Review
- Future challenges and chances in the diagnosis and management of invasive mould infections in cancer patients.Medical mycology · 2021Article
- Management of Multidrug Resistant Infections in Lung Transplant Recipients with Cystic Fibrosis.Infection and drug resistance · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
APX001, the prodrug of APX001A, is a first-in-class antifungal agent that has a potent activity against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.